New compounds to target specific proteins in acute myeloid leukemia
3H-pyrazolo[4,3-f]quinoline-containing compounds as selective and tunable protein kinase inhibitors
This study is looking at new medicines that could help treat acute myeloid leukemia (AML) by blocking certain proteins that help cancer cells grow, aiming to find better options for patients, especially those with tough-to-treat mutations.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Notre Dame NIH-funded |
| Lab location | 1 site (Notre Dame, United States) |
| Project ID | NIH-11267484 on NIH RePORTER |
What this research studies
This research focuses on developing novel compounds that selectively inhibit specific protein kinases involved in acute myeloid leukemia (AML). The approach involves synthesizing 3H-pyrazolo[4,3-f]quinoline-based inhibitors that target FLT3 and other kinases, which are crucial for the growth of cancer cells. By understanding how these compounds work, the research aims to provide more effective treatment options for patients with AML, particularly those with mutations that lead to poor outcomes. The methodology includes laboratory testing of these compounds to evaluate their effectiveness and safety.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia, especially those with FLT3 mutations.
Not a fit: Patients with other types of leukemia or those who do not have acute myeloid leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, more effective treatments for patients with acute myeloid leukemia, potentially improving survival rates.
How similar studies have performed: Other research has shown promise in targeting specific kinases in leukemia, indicating that this approach could be effective.
Where this research is happening
Notre Dame, United States
- University of Notre Dame — Notre Dame, United States (Active)
Researchers
- Principal investigator: Sintim, Herman O — University of Notre Dame
- Study coordinator: Sintim, Herman O
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.